Ferrone S, Kageshita T, Hirai S
Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.
J Dermatol. 1993 Sep;20(9):533-9. doi: 10.1111/j.1346-8138.1993.tb01334.x.
In this study, we have utilized the human high molecular weight-melanoma associated antigen (HMW-MAA) as a target for active specific immunotherapy with mouse anti-idiotypic (anti-id) monoclonal antibodies (mAb) in patients with malignant melanoma. After having summarized the characteristics of HMW-MAA which account for its selection as a target for immunotherapy, we describe the development and characterization of mouse anti-id mAb MK2-23 which bears the internal image of HMW-MAA. Furthermore, we describe the results of the first clinical trial performed with mouse anti-id mAb MK2-23 in patients with malignant melanoma.
在本研究中，我们将人类高分子量黑色素瘤相关抗原（HMW-MAA）作为靶点，用小鼠抗独特型（抗-id）单克隆抗体（mAb）对恶性黑色素瘤患者进行主动特异性免疫治疗。在总结了HMW-MAA的特性（这些特性使其被选作免疫治疗靶点）之后，我们描述了具有HMW-MAA内影像的小鼠抗-id mAb MK2-23的研制及特性鉴定。此外，我们还描述了用小鼠抗-id mAb MK2-23对恶性黑色素瘤患者进行的首例临床试验结果。
